Abstract
A review summarised extensive clinical, published and as yet unpublished data on the use of ambroxol in children and evaluated the results. Ambroxol was shown to be an effective secretolytic treatment in children with acute and chronic respiratory diseases. Based on the continuous monitoring of ambroxol safety over many years, the drug showed a favourable benefit-risk profile in adults and children of any age.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
